Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BYM338 in COPD-associated cachexia (Phase 2)
2011-000461-12Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cachexia comparing BYM338 with Placebo (2 arms). Primary endpoint: Thigh muscle volume assessed by MRI. Started Nov 2012; status: completed.
02
Drugs
bimagrumab
03
Conditions
cachexia
Beyond the preview
Go deeper on 2011-000461-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000461-12.